On the public citation graph
Accelerated transport and maturation of lysosomal α–galactosidase A in Fabry lymphoblasts by an enzyme inhibitor
0 signed · 614 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1006/abio.1997.2022openalex-snapshot
[14C]Ceramide Synthesis by Sphingolipid CeramideN-Deacylase: New Assay for Ceramidase Activity Detection
inferredcites →https://doi.org/10.1006/bbrc.1993.2659openalex-snapshot
Characterization of a Mutant α-Galactosidase Gene Product for the Late-Onset Cardiac Form of Fabry Disease
inferredcites →https://doi.org/10.1006/bbrc.1996.0486openalex-snapshot
Aggregation of the Inactive Form of Human α-Galactosidase in the Endoplasmic Reticulum
inferredcites →https://doi.org/10.1007/bf00207037openalex-snapshot
Point mutations in the upstream region of the ?-galactosidase A gene exon 6 in an atypical variant of Fabry disease
inferredcites →https://doi.org/10.1007/bf00210592openalex-snapshot
Intracellular processing and maturation of mutant gene products in hereditary ?-galactosidase deficiency (?-galactosidosis)
inferredcites →https://doi.org/10.1007/bf00484919openalex-snapshot
Residual activity of α-galactosidase A in Fabry's disease
inferredcites →https://doi.org/10.1016/0005-2760(95)00217-0openalex-snapshot
Induction of glucosylceramide synthase by synthase inhibitors and ceramide
inferredcites →https://doi.org/10.1016/0076-6879(74)31005-1openalex-snapshot
[2] Subcellular fractionation of rat liver
inferredcites →https://doi.org/10.1016/s0021-9258(18)61618-7openalex-snapshot
Synthesis and processing of alpha-galactosidase A in human fibroblasts. Evidence for different mutations in Fabry disease.
inferredcites →https://doi.org/10.1021/bi00335a022openalex-snapshot
Reversible inhibitors of .beta.-glucosidase
inferredcites →https://doi.org/10.1021/jm00048a006openalex-snapshot
Nitrogen-in-the-Ring Pyranoses and Furanoses: Structural Basis of Inhibition of Mammalian Glycosidases
inferredcites →https://doi.org/10.1021/np960577nopenalex-snapshot
Homonojirimycin Isomers and Glycosides from Aglaonema treubii
inferredcites →https://doi.org/10.1023/a:1006915926732openalex-snapshot
α-Galactosidase transgenic mouse: Heterogeneous gene expression and posttranslational glycosylation in tissues
inferredcites →https://doi.org/10.1038/nm0598-610openalex-snapshot
Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking
inferredcites →https://doi.org/10.1056/nejm196705252762101openalex-snapshot
Enzymatic Defect in Fabry's Disease
inferredcites →https://doi.org/10.1073/pnas.87.7.2725openalex-snapshot
Analysis of cytokine mRNA and DNA: detection and quantitation by competitive polymerase chain reaction.
inferredcites →https://doi.org/10.1146/annurev.cb.05.110189.001425openalex-snapshot
Protein Oligomerization in the Endoplasmic Reticulum
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4647251openalex-extracted
First Example of Multivalent Pyrrolidines Acting as Pharmacological Chaperones Against Gaucher Disease
inferred← citeshttps://doi.org/10.1002/9780470048672.wecb667openalex-snapshot
Protein Trafficking Diseases: Small Molecule Approaches
inferred← citeshttps://doi.org/10.1002/9780470048672.wecb723openalex-snapshot
Role of Chemical Biology in Understanding and Treating Disease
inferred← citeshttps://doi.org/10.1002/9780470627327.ch17openalex-snapshot
Pharmacological Chaperones: Potential for the Treatment of Hereditary Diseases Caused by Mutations in G Protein‐Coupled Receptors
inferred← citeshttps://doi.org/10.1002/9781118063903.ch12openalex-snapshot
Therapeutics: Harnessing the Power of Molecular and Pharmacological Chaperones
inferred← citeshttps://doi.org/10.1002/9781118435762.ch11openalex-snapshot
The Role of Chemical Biology in Understanding and Treating Disease‐Are Small Molecule “Correctors” the Way of the Future?
inferred← citeshttps://doi.org/10.1002/9781118435762.ch20openalex-snapshot
Protein Trafficking Diseases
inferred← citeshttps://doi.org/10.1002/9781118978320.ch15openalex-snapshot
Pharmacological Chaperones as Potential Therapeutics for Lysosomal Storage Disorders: Preclinical Research to Clinical Studies
inferred← citeshttps://doi.org/10.1002/9781118981559.ch20openalex-snapshot
Prenatal Diagnosis of Disorders of Lipid Metabolism
inferred← citeshttps://doi.org/10.1002/9781119013112.ch29openalex-snapshot
Sphingolipidoses and Related Disorders
inferred← citeshttps://doi.org/10.1002/9781444314342.ch12openalex-snapshot
Prenatal Diagnosis of Disorders of Lipid Metabolism
inferred← citeshttps://doi.org/10.1002/9783527621071.ch5openalex-snapshot
Glycosidase‐Inhibiting Alkaloids: Isolation, Structure, and Application
inferred← citeshttps://doi.org/10.1002/9783527831326.ch9openalex-snapshot
Carbohydrate‐Based Therapeutics for Lysosomal Storage Disorders
inferred← citeshttps://doi.org/10.1002/acn3.292openalex-snapshot
Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study
inferred← citeshttps://doi.org/10.1002/ajmg.a.34053openalex-snapshot
Residual activity and proteasomal degradation of p.Ser298Pro sulfamidase identified in patients with a mild clinical phenotype of Sanfilippo A syndrome
inferred← citeshttps://doi.org/10.1002/ajoc.201700080openalex-snapshot
Preparation of a Stable Bicyclic Aziridinium Ion and Its Ring Expansion toward Piperidines and Azepanes
inferred← citeshttps://doi.org/10.1002/ana.21284openalex-snapshot
Chemical chaperone therapy: clinical effect in murine GM1‐gangliosidosis
inferred← citeshttps://doi.org/10.1002/ange.200351002openalex-snapshot
Nitrogen Inversion as a Diastereomeric Relay in Azasugar Synthesis: The First Synthesis of Adenophorine
inferred← citeshttps://doi.org/10.1002/ange.200502662openalex-snapshot
Rational Design and Synthesis of Highly Potent β‐Glucocerebrosidase Inhibitors
inferred← citeshttps://doi.org/10.1002/ange.200902620openalex-snapshot
Glycosphingolipide – Natur, Funktion und pharmakologische Modulierung
inferred← citeshttps://doi.org/10.1002/anie.200351002openalex-snapshot
Nitrogen Inversion as a Diastereomeric Relay in Azasugar Synthesis: The First Synthesis of Adenophorine
inferred← citeshttps://doi.org/10.1002/anie.200502662openalex-snapshot
Rational Design and Synthesis of Highly Potent β‐Glucocerebrosidase Inhibitors
inferred← citeshttps://doi.org/10.1002/anie.200902620openalex-snapshot
Glycosphingolipids—Nature, Function, and Pharmacological Modulation
inferred← citeshttps://doi.org/10.1002/asia.202401091openalex-snapshot
A Supramolecular Gel‐Based Protocol for the Detection of α‐Glycosidases for Screening Potential Drugs
inferred← citeshttps://doi.org/10.1002/cbic.200390045openalex-snapshot
Chemical Chaperones—A New Concept in Drug Research
inferred← citeshttps://doi.org/10.1002/cbic.200600217openalex-snapshot
Design and Synthesis of Highly Potent and Selective Pharmacological Chaperones for the Treatment of Gaucher's disease
inferred← citeshttps://doi.org/10.1002/cbic.200800304openalex-snapshot
Identification of Pharmacological Chaperones for Gaucher Disease and Characterization of Their Effects on β‐Glucocerebrosidase by Hydrogen/Deuterium Exchange Mass Spectrometry
inferred← citeshttps://doi.org/10.1002/cbic.200900442openalex-snapshot
Chaperone Activity of Bicyclic Nojirimycin Analogues for Gaucher Mutations in Comparison with N‐(n‐nonyl)Deoxynojirimycin
inferred← citeshttps://doi.org/10.1002/cbic.201000323openalex-snapshot
A Fluorescent sp2‐Iminosugar With Pharmacological Chaperone Activity for Gaucher Disease: Synthesis and Intracellular Distribution Studies
inferred← citeshttps://doi.org/10.1002/cbic.201200005openalex-snapshot
Cyclodextrin‐Based Iminosugar Click Clusters: The First Examples of Multivalent Pharmacological Chaperones for the Treatment of Lysosomal Storage Disorders
inferred← citeshttps://doi.org/10.1002/cbic.201300197openalex-snapshot
New Insights into the Pharmacological Chaperone Activity of C2‐Substituted Glucoimidazoles for the Treatment of Gaucher Disease
inferred← citeshttps://doi.org/10.1002/cbic.201300442openalex-snapshot
A Systematic Investigation of Iminosugar Click Clusters as Pharmacological Chaperones for the Treatment of Gaucher Disease
inferred← citeshttps://doi.org/10.1002/cbic.201500292openalex-snapshot
Human Acid β‐Glucosidase Inhibition by Carbohydrate Derived Iminosugars: Towards New Pharmacological Chaperones for Gaucher Disease
inferred← citeshttps://doi.org/10.1002/chem.201200279openalex-snapshot
sp2‐Iminosugar O‐, S‐, and N‐Glycosides as Conformational Mimics of α‐Linked Disaccharides; Implications for Glycosidase Inhibition
inferred← citeshttps://doi.org/10.1002/cmdc.200600195openalex-snapshot
Chemical Tools to Investigate Sphingolipid Metabolism and Functions
inferred← citeshttps://doi.org/10.1002/cmdc.200800350openalex-snapshot
Design, Synthesis, and Biological Evaluation of Enantiomeric β‐N‐Acetylhexosaminidase Inhibitors LABNAc and DABNAc as Potential Agents against Tay‐Sachs and Sandhoff Disease
inferred← citeshttps://doi.org/10.1002/cpdd.147openalex-snapshot
Relative bioavailability and the effect of meal type and timing on the pharmacokinetics of migalastat in healthy volunteers
inferred← citeshttps://doi.org/10.1002/cpt.1321openalex-snapshot
Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year
inferred← citeshttps://doi.org/10.1002/ejoc.200200518openalex-snapshot
Bioorganic Chemistry of Ceramide
inferred← citeshttps://doi.org/10.1002/ejoc.200800796openalex-snapshot
Efficient and Stereodivergent Syntheses of D ‐ and L ‐Fagomines and Their Analogues
inferred← citeshttps://doi.org/10.1002/ejoc.201300878openalex-snapshot
Exploring a Multivalent Approach to α‐ L ‐Fucosidase Inhibition
inferred← citeshttps://doi.org/10.1002/ejoc.201402521openalex-snapshot
Stereoselective Synthesis of Enantiopure Oxetanes, a Carbohydrate Mimic, an ϵ‐Lactone, and Cyclitols from Biocatalytically Derived β‐Hydroxy Esters as Chiral Precursors
inferred← citeshttps://doi.org/10.1002/ejoc.201701073openalex-snapshot
On the Asymmetric Induction in Proline‐Catalyzed Aldol Reactions: Reagent‐Controlled Addition Reactions of 2,2‐Dimethyl‐1,3‐dioxane‐5‐one to Acyclic Chiral α‐Branched Aldehydes
inferred← citeshttps://doi.org/10.1002/ejoc.202100398openalex-snapshot
Combining Organocatalyzed Aldolization and Reductive Amination: An Efficient Reaction Sequence for the Synthesis of Iminosugars
inferred← citeshttps://doi.org/10.1002/emmm.200900036openalex-snapshot
Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics
inferred← citeshttps://doi.org/10.1002/hep.21628openalex-snapshot
Molecular pathogenesis of alpha‐1‐antitrypsin deficiency‐associated liver disease
inferred← citeshttps://doi.org/10.1002/hlca.200490078openalex-snapshot
Syntheses and Glycosidase Inhibitory Activities of 2‐(Aminomethyl)‐5‐(hydroxymethyl)pyrrolidine‐3,4‐diol Derivatives
inferred← citeshttps://doi.org/10.1002/humu.10197openalex-snapshot
HowPAH gene mutations cause hyper-phenylalaninemia and why mechanism matters: Insights from in vitro expression
inferred← citeshttps://doi.org/10.1002/humu.21251openalex-snapshot
Functional consequences and rescue potential of pathogenic missense mutations in tripeptidyl peptidase I
inferred← citeshttps://doi.org/10.1002/humu.21516openalex-snapshot
Chemical chaperone therapy: chaperone effect on mutant enzyme and cellular pathophysiology in β-galactosidase deficiency
inferred← citeshttps://doi.org/10.1002/humu.21530openalex-snapshot
A pharmacogenetic approach to identify mutant forms of α‐galactosidase a that respond to a pharmacological chaperone for Fabry disease
inferred← citeshttps://doi.org/10.1002/humu.9520openalex-snapshot
Novel mutations of the GLA gene in Japanese patients with Fabry disease and their functional characterization by active site specific chaperone
inferred← citeshttps://doi.org/10.1002/iub.284openalex-snapshot
Therapy for lysosomal storage disorders
inferred← citeshttps://doi.org/10.1002/j.1536-4801.2002.tb07797.xopenalex-snapshot
Metabolic Liver Disease: Working Group Report of the First World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition
inferred← citeshttps://doi.org/10.1002/jcp.22856openalex-snapshot
Molecular chaperones as therapeutic targets to counteract proteostasis defects
inferred← citeshttps://doi.org/10.1002/jha2.852openalex-snapshot
The use of Ambroxol for the treatment of Gaucher disease: A systematic review
inferred← citeshttps://doi.org/10.1002/jimd.12228openalex-snapshot
Developments in the treatment of Fabry disease
inferred← citeshttps://doi.org/10.1002/jimd.12773openalex-snapshot
Clinical outcomes in patients switching from agalsidase beta to migalastat: A Fabry Registry analysis
inferred← citeshttps://doi.org/10.1002/jimd.70043openalex-snapshot
Novel Treatment Strategy for Patients With Urea Cycle Disorders: Pharmacological Chaperones Enhance Enzyme Stability and Activity in Patient‐Derived Liver Disease Models
inferred← citeshttps://doi.org/10.1002/jmr.2624openalex-snapshot
Characterization of surface binding sites in glycoside hydrolases: A computational study
inferred← citeshttps://doi.org/10.1002/jnr.23755openalex-snapshot
Chaperones as potential therapeutics for Krabbe disease
inferred← citeshttps://doi.org/10.1002/jnr.23762openalex-snapshot
New therapeutic approaches for Krabbe disease: The potential of pharmacological chaperones
inferred← citeshttps://doi.org/10.1002/slct.201701818openalex-snapshot
Diastereoselective Carbamate Annulation for the Synthesis of 2,5‐Dideoxy‐2,5‐iminoglycitols
inferred← citeshttps://doi.org/10.1002/tcr.202100269openalex-snapshot
Pharmacological Chaperones for β‐Galactosidase Related to GM1‐Gangliosidosis and Morquio B: Recent Advances
inferred← citeshttps://doi.org/10.1006/abbi.2000.1743openalex-snapshot
Role of Ser-65 in the Activity of α-Galactosidase A: Characterization of a Point Mutation (S65T) Detected in a Patient with Fabry Disease
inferred← citeshttps://doi.org/10.1007/0-387-28957-7_10openalex-snapshot
Therapy of Lysosomal Storage Diseases
inferred← citeshttps://doi.org/10.1007/3-540-29717-0_16openalex-snapshot
Chemical Chaperones: Mechanisms of Action and Potential Use
inferred← citeshttps://doi.org/10.1007/4735_90openalex-snapshot
Proteasomal degradation of misfolded proteins
inferred← citeshttps://doi.org/10.1007/8904_2011_49openalex-snapshot
Treatment of Human Fibroblasts Carrying NPC1 Missense Mutations with MG132 Leads to an Improvement of Intracellular Cholesterol Trafficking
inferred← citeshttps://doi.org/10.1007/978-0-387-30378-9_27openalex-snapshot
Sphingolipid-Inherited Diseases of the Central Nervous System
inferred← citeshttps://doi.org/10.1007/978-0-387-36534-3_17openalex-snapshot
Understanding the Effects of Cancer-Associated Mutations in the Tumor Suppressor Protein p53: Structural Consequences of Mutations and Possible Ways of Rescuing Oncogenic Mutants
inferred← citeshttps://doi.org/10.1007/978-1-4020-2922-6_17openalex-snapshot
Wild Type p53 Conformation, Structural Consequences of p53 Mutations and Mechanisms of Mutant p53 Rescue
inferred← citeshttps://doi.org/10.1007/978-1-4419-7107-4_46openalex-snapshot
α1-Antitrypsin Deficiency
inferred← citeshttps://doi.org/10.1007/978-1-59259-919-6_3openalex-snapshot
GPCR Folding and Maturation
inferred← citeshttps://doi.org/10.1007/978-1-59745-197-0_2openalex-snapshot
Upregulation of Opioid Receptors
inferred← citeshttps://doi.org/10.1007/978-3-030-80662-0_17openalex-snapshot
Therapy for Neuropathic Lysosomal Storage Diseases
inferred← citeshttps://doi.org/10.1007/978-3-540-30429-6_48openalex-snapshot
Azaglycomimetics: Natural Occurrence, Biological Activity, and Application
inferred← citeshttps://doi.org/10.1007/978-3-642-56874-9_62openalex-snapshot
Azaglycomimetics: Synthesis and Chemical Biology
inferred← citeshttps://doi.org/10.1007/978-81-322-2467-9_5openalex-snapshot
Protein Folding: From Normal Cellular Function to Pathophysiology
inferred← citeshttps://doi.org/10.1007/978-90-481-9033-1_29openalex-snapshot
Pharmacological Chaperone Therapy for Fabry Disease
inferred← citeshttps://doi.org/10.1007/978-90-481-9033-1_9openalex-snapshot
Small Molecule Drug Discovery for Fabry Disease
inferred← citeshttps://doi.org/10.1007/s00018-008-7470-2openalex-snapshot
Chemical chaperone therapy for GM1-gangliosidosis
inferred← citeshttps://doi.org/10.1007/s00018-008-8522-3openalex-snapshot
Sugar-mimicking glycosidase inhibitors: bioactivity and application
inferred← citeshttps://doi.org/10.1007/s00418-007-0366-7openalex-snapshot
Protein quality control: the who’s who, the where’s and therapeutic escapes
inferred← citeshttps://doi.org/10.1007/s00706-019-02428-0openalex-snapshot
Biologically active branched-chain aminocyclopentane tetraols from d-galactose
inferred← citeshttps://doi.org/10.1007/s00706-024-03187-3openalex-snapshot
A short and efficient formal synthesis of (R)-pipecolic acid from the ring expansion of chiral aziridine
inferred← citeshttps://doi.org/10.1007/s10157-019-01810-wopenalex-snapshot
Efficacy and safety of migalastat in a Japanese population: a subgroup analysis of the ATTRACT study
inferred← citeshttps://doi.org/10.1007/s10545-006-0287-yopenalex-snapshot
β‐Galactosidase deficiency: An approach to chaperone therapy
inferred← citeshttps://doi.org/10.1007/s10545-006-0440-7openalex-snapshot
Effect of Hunter disease (mucopolysaccharidosis type II) mutations on molecular phenotypes of iduronate‐2‐sulfatase: Enzymatic activity, protein processing and structural analysis
inferred← citeshttps://doi.org/10.1007/s10545-009-1077-0openalex-snapshot
The pharmacological chaperone 1‐deoxygalactonojirimycin increases α‐galactosidase A levels in Fabry patient cell lines
inferred← citeshttps://doi.org/10.1007/s10545-010-9185-4openalex-snapshot
Phenylketonuria as a model for protein misfolding diseases and for the development of next generation orphan drugs for patients with inborn errors of metabolism
inferred← citeshttps://doi.org/10.1007/s10545-011-9424-3openalex-snapshot
Synergy between the pharmacological chaperone 1‐deoxygalactonojirimycin and the human recombinant alpha‐galactosidase A in cultured fibroblasts from patients with Fabry disease
inferred← citeshttps://doi.org/10.1007/s10545-014-9701-zopenalex-snapshot
Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators
inferred← citeshttps://doi.org/10.1007/s10545-014-9718-3openalex-snapshot
Treatment of lysosomal storage disorders: successes and challenges
inferred← citeshttps://doi.org/10.1007/s10545-017-0032-8openalex-snapshot
Enzyme replacement therapy and beyond—in memoriam Roscoe O. Brady, M.D. (1923–2016)
inferred← citeshttps://doi.org/10.1007/s10863-005-9499-3openalex-snapshot
Rescue of Folding Defects in ABC Transporters Using Pharmacological Chaperones
inferred← citeshttps://doi.org/10.1007/s11938-000-0033-8openalex-snapshot
Alphain1-antitrypsin deficiency
inferred← citeshttps://doi.org/10.1007/s12017-010-8133-7openalex-snapshot
Pathology and Current Treatment of Neurodegenerative Sphingolipidoses
inferred← citeshttps://doi.org/10.1007/s12033-007-9008-5openalex-snapshot
Naked Plasmid DNA-Based α-Galactosidase A Gene Transfer Partially Reduces Systemic Accumulation of Globotriaosylceramide in Fabry Mice
inferred← citeshttps://doi.org/10.1007/s12035-013-8605-5openalex-snapshot
Chaperone Therapy for GM2 Gangliosidosis: Effects of Pyrimethamine on β-Hexosaminidase Activity in Sandhoff Fibroblasts
inferred← citeshttps://doi.org/10.1007/s13730-020-00510-9openalex-snapshot
A case of latent heterozygous Fabry disease in a female living kidney donor candidate
inferred← citeshttps://doi.org/10.1007/s40139-017-0147-5openalex-snapshot
Liver Disease in Alpha-1 Antitrypsin Deficiency: Current Approaches and Future Directions
inferred← citeshttps://doi.org/10.1007/s40259-013-0032-7openalex-snapshot
Gene Therapy for Fabry Disease: A Review of the Literature
inferred← citeshttps://doi.org/10.1007/s40259-024-00678-xopenalex-snapshot
Biochemical Amenability in Fabry Patients Under Chaperone Therapy—How and When to Test?
inferred← citeshttps://doi.org/10.1007/s40259-025-00723-3openalex-snapshot
Progress and Challenges in the Treatment of Fabry Disease
inferred← citeshttps://doi.org/10.1007/s40265-019-01090-4openalex-snapshot
Migalastat: A Review in Fabry Disease
inferred← citeshttps://doi.org/10.1007/s40265-021-01486-1openalex-snapshot
Fabry Disease: The Current Treatment Landscape
inferred← citeshttps://doi.org/10.1007/s40266-019-00684-7openalex-snapshot
Alpha-1 Antitrypsin Deficiency and Accelerated Aging: A New Model for an Old Disease?
inferred← citeshttps://doi.org/10.1007/s40290-026-00611-3openalex-snapshot
Optimising Formulations for Paediatric Patients with Inherited Metabolic Disorders: The Case Study of Levocarnitine
inferred← citeshttps://doi.org/10.1016/b978-0-12-383834-6.00036-7openalex-snapshot
Therapies for Lysosomal Storage Diseases
inferred← citeshttps://doi.org/10.1016/b978-0-12-409547-2.02835-3openalex-snapshot
Molecular Probes for Protein Glycosylation
inferred← citeshttps://doi.org/10.1016/b978-0-12-409547-2.14947-9openalex-snapshot
Folding and Quality Control of Glycoproteins
inferred← citeshttps://doi.org/10.1016/b978-0-12-449851-8.00035-8openalex-snapshot
Fabry Disease (α-Galactosidase A Deficiency)
inferred← citeshttps://doi.org/10.1016/b978-0-12-802761-5.00027-4openalex-snapshot
Molecular Basis of Skin Disease
inferred← citeshttps://doi.org/10.1016/b978-0-12-812536-6.00007-9openalex-snapshot
Therapies for Lysosomal Storage Diseases
inferred← citeshttps://doi.org/10.1016/b978-0-12-813257-9.00027-9openalex-snapshot
Molecular basis of skin disease
inferred← citeshttps://doi.org/10.1016/b978-0-12-813955-4.00042-8openalex-snapshot
Fabry disease: α-galactosidase A deficiency
inferred← citeshttps://doi.org/10.1016/b978-0-12-816675-8.00010-5openalex-snapshot
Carbo-click in drug discovery and development: Opportunities and challenges
inferred← citeshttps://doi.org/10.1016/b978-0-12-819132-3.00013-0openalex-snapshot
Structure-guided discovery of pharmacological chaperones targeting protein conformational and misfolding diseases
inferred← citeshttps://doi.org/10.1016/b978-0-12-819132-3.00016-6openalex-snapshot
Cellular high-throughput screening
inferred← citeshttps://doi.org/10.1016/b978-0-12-819475-1.00061-4openalex-snapshot
Glycan Arrays: Construction, Detection, and Analysis
inferred← citeshttps://doi.org/10.1016/b978-0-443-19041-4.00079-0openalex-snapshot
Fabry disease: α-galactosidase A deficiency
inferred← citeshttps://doi.org/10.1016/b978-008045382-8.00125-8openalex-snapshot
Molecular Probes for Protein Glycosylation
inferred← citeshttps://doi.org/10.1016/b978-008045382-8.00649-3openalex-snapshot
Alkaloid Glycosidase Inhibitors
inferred← citeshttps://doi.org/10.1016/b978-012352551-2/50030-5openalex-snapshot
THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (ABCC7)
inferred← citeshttps://doi.org/10.1016/b978-044451967-2/00046-5openalex-snapshot
Folding and Quality Control of Glycoproteins
inferred← citeshttps://doi.org/10.1016/b978-044451967-2/00100-8openalex-snapshot
Glycosidase Inhibitors: Structure, Activity, Synthesis, and Medical Relevance
inferred← citeshttps://doi.org/10.1016/bs.accb.2016.08.002openalex-snapshot
Carbohydrate-Processing Enzymes of the Lysosome
inferred← citeshttps://doi.org/10.1016/bs.pmbts.2022.03.003openalex-snapshot
Mutations in melanocortin-4 receptor: From fish to men
inferred← citeshttps://doi.org/10.1016/j.bbadis.2004.03.007openalex-snapshot
N-Octyl-β-valienamine up-regulates activity of F213I mutant β-glucosidase in cultured cells: a potential chemical chaperone therapy for Gaucher disease
inferred← citeshttps://doi.org/10.1016/j.bbadis.2004.07.001openalex-snapshot
Transgenic mouse expressing human mutant α-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease
inferred← citeshttps://doi.org/10.1016/j.bbadis.2005.05.002openalex-snapshot
Lysosomal leukocyte β-d-glucuronidase during enzyme replacement therapy in Fabry disease
inferred← citeshttps://doi.org/10.1016/j.bbadis.2007.02.003openalex-snapshot
Enzyme enhancement activity of N-octyl-β-valienamine on β-glucosidase mutants associated with Gaucher disease
inferred← citeshttps://doi.org/10.1016/j.bbadis.2008.03.001openalex-snapshot
Rescue of mutant α-galactosidase A in the endoplasmic reticulum by 1-deoxygalactonojirimycin leads to trafficking to lysosomes
inferred← citeshttps://doi.org/10.1016/j.bbagen.2019.129437openalex-snapshot
Progress in the understanding and treatment of Fabry disease
inferred← citeshttps://doi.org/10.1016/j.bbalip.2013.10.015openalex-snapshot
Sphingolipids and lysosomal pathologies
inferred← citeshttps://doi.org/10.1016/j.bbamem.2006.05.027openalex-snapshot
Sphingolipid metabolism diseases
inferred← citeshttps://doi.org/10.1016/j.bbapap.2006.08.012openalex-snapshot
Small molecule pharmacological chaperones: From thermodynamic stabilization to pharmaceutical drugs
inferred← citeshttps://doi.org/10.1016/j.bbrc.2007.05.082openalex-snapshot
Screening for pharmacological chaperones in Fabry disease
inferred← citeshttps://doi.org/10.1016/j.bbrc.2007.06.048openalex-snapshot
4-Phenylbutyrate rescues trafficking incompetent mutant α-galactosidase A without restoring its functionality
inferred← citeshttps://doi.org/10.1016/j.bbrc.2011.10.038openalex-snapshot
Proteasome inhibitors improve the function of mutant lysosomal α-glucosidase in fibroblasts from Pompe disease patient carrying c.546G>T mutation
inferred← citeshttps://doi.org/10.1016/j.bcmd.2005.05.007openalex-snapshot
Miglustat (NB-DNJ) works as a chaperone for mutated acid β-glucosidase in cells transfected with several Gaucher disease mutations
inferred← citeshttps://doi.org/10.1016/j.bcmd.2008.11.002openalex-snapshot
Promising results of the chaperone effect caused by iminosugars and aminocyclitol derivatives on mutant glucocerebrosidases causing Gaucher disease
inferred← citeshttps://doi.org/10.1016/j.bcmd.2009.10.003openalex-snapshot
The pharmacological chaperone effect of N-octyl-β-valienamine on human mutant acid β-glucosidases
inferred← citeshttps://doi.org/10.1016/j.bcp.2026.118323openalex-snapshot
Pain in Fabry disease: do experimental models reveal novel therapeutic targets?
inferred← citeshttps://doi.org/10.1016/j.biochi.2015.03.018openalex-snapshot
Taming molecular flexibility to tackle rare diseases
inferred← citeshttps://doi.org/10.1016/j.biochi.2016.09.011openalex-snapshot
Alterations in membrane trafficking and pathophysiological implications in lysosomal storage disorders
inferred← citeshttps://doi.org/10.1016/j.bioorg.2024.107295openalex-snapshot
Multivalent pyrrolidines acting as pharmacological chaperones against Gaucher disease
inferred← citeshttps://doi.org/10.1016/j.biopha.2020.110779openalex-snapshot
Therapeutic advances in Fabry disease: The future awaits
inferred← citeshttps://doi.org/10.1016/j.bmc.2003.12.016openalex-snapshot
Convenient synthesis and evaluation of glycosidase inhibitory activity of α- and β-galactose-type valienamines, and some N-alkyl derivatives
inferred← citeshttps://doi.org/10.1016/j.bmc.2003.12.040openalex-snapshot
Design and synthesis of 2-acetamidomethyl derivatives of isofagomine as potential inhibitors of human lysosomal β-hexosaminidases
inferred← citeshttps://doi.org/10.1016/j.bmc.2006.05.080openalex-snapshot
Search for α-glucosidase inhibitors: New N-substituted valienamine and conduramine F-1 derivatives
inferred← citeshttps://doi.org/10.1016/j.bmc.2006.08.003openalex-snapshot
α-1-C-Octyl-1-deoxynojirimycin as a pharmacological chaperone for Gaucher disease
inferred← citeshttps://doi.org/10.1016/j.bmc.2008.06.026openalex-snapshot
In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures
inferred← citeshttps://doi.org/10.1016/j.bmc.2013.05.056openalex-snapshot
Three dimensional structure of a bacterial α-l-fucosidase with a 5-membered iminocyclitol inhibitor
inferred← citeshttps://doi.org/10.1016/j.bmc.2013.06.022openalex-snapshot
Structure–activity relationship studies of Niemann-Pick type C1-like 1 (NPC1L1) ligands identified by screening assay monitoring pharmacological chaperone effect
inferred← citeshttps://doi.org/10.1016/j.bmc.2013.06.054openalex-snapshot
Rapid modifications of N-substitution in iminosugars: Development of new β-glucocerebrosidase inhibitors and pharmacological chaperones for Gaucher disease
inferred← citeshttps://doi.org/10.1016/j.bmc.2014.02.057openalex-snapshot
Docking and SAR studies of calystegines: Binding orientation and influence on pharmacological chaperone effects for Gaucher’s disease
inferred← citeshttps://doi.org/10.1016/j.bmcl.2010.11.112openalex-snapshot
The synthesis and biological evaluation of 1-C-alkyl-l-arabinoiminofuranoses, a novel class of α-glucosidase inhibitors
inferred← citeshttps://doi.org/10.1016/j.bmcl.2014.05.064openalex-snapshot
Structure–activity relationships of oxysterol-derived pharmacological chaperones for Niemann–Pick type C1 protein
inferred← citeshttps://doi.org/10.1016/j.bmcl.2017.05.086openalex-snapshot
A new type of pharmacological chaperone for GM1-gangliosidosis related human lysosomal β-galactosidase: N-Substituted 5-amino-1-hydroxymethyl-cyclopentanetriols
inferred← citeshttps://doi.org/10.1016/j.bmcl.2022.128571openalex-snapshot
Amyloidogenic immunoglobulin light chain kinetic stabilizers comprising a simple urea linker module reveal a novel binding sub-site
inferred← citeshttps://doi.org/10.1016/j.bmcl.2025.130426openalex-snapshot
In vitro comparison of the glycosidase inhibitory profile of isoiminosugars with their 1- and 5a-modified derivatives
inferred← citeshttps://doi.org/10.1016/j.bpc.2022.106915openalex-snapshot
A theoretical study on binding and stabilization of galactose and novel galactose analogues to the human α-galactosidase A variant causing Fabry disease
inferred← citeshttps://doi.org/10.1016/j.braindev.2004.01.005openalex-snapshot
Recent advances in the biochemistry and genetics of sphingolipidoses
inferred← citeshttps://doi.org/10.1016/j.braindev.2006.02.002openalex-snapshot
Fibroblast screening for chaperone therapy in β-galactosidosis
inferred← citeshttps://doi.org/10.1016/j.braindev.2006.08.014openalex-snapshot
Motor and reflex testing in GM1-gangliosidosis model mice
inferred← citeshttps://doi.org/10.1016/j.braindev.2009.12.005openalex-snapshot
The effect of N-octyl-β-valienamine on β-glucosidase activity in tissues of normal mice
inferred← citeshttps://doi.org/10.1016/j.braindev.2011.01.007openalex-snapshot
Molecular basis of neurogenetic diseases
inferred← citeshttps://doi.org/10.1016/j.braindev.2012.12.002openalex-snapshot
Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease
inferred← citeshttps://doi.org/10.1016/j.braindev.2020.06.015openalex-snapshot
Chaperone therapy for molecular pathology in lysosomal diseases
inferred← citeshttps://doi.org/10.1016/j.braindev.2023.02.004openalex-snapshot
Chaperone therapy for lysosomal and non-lysosomal protein misfolding diseases
inferred← citeshttps://doi.org/10.1016/j.braindev.2024.10.006openalex-snapshot
Chaperone therapy: Stabilization and enhancement of endogenous and exogenous lysosomal enzymes
inferred← citeshttps://doi.org/10.1016/j.brainres.2006.11.039openalex-snapshot
Cerebrospinal fluid biomarkers showing neurodegeneration in dogs with GM1 gangliosidosis: Possible use for assessment of a therapeutic regimen
inferred← citeshttps://doi.org/10.1016/j.carres.2007.03.015openalex-snapshot
Synthesis of 4-O-glycosylated 1-deoxynojirimycin derivatives as disaccharide mimics-based inhibitors of human β-glucocerebrosidase
inferred← citeshttps://doi.org/10.1016/j.carres.2008.07.013openalex-snapshot
Synthesis of iminoalditol analogues of galactofuranosides and their activities against glycosidases
inferred← citeshttps://doi.org/10.1016/j.carres.2010.01.021openalex-snapshot
Synthesis of N-substituted iminosugar derivatives and their immunosuppressive activities
inferred← citeshttps://doi.org/10.1016/j.carres.2012.03.015openalex-snapshot
I2-mediated carbamate annulation: scope and application in the synthesis of azasugars
inferred← citeshttps://doi.org/10.1016/j.carres.2012.12.010openalex-snapshot
Concise syntheses of potent chaperone drug candidates, N-octyl-4-epi-β-valinenamine (NOEV) and its 6-deoxy derivative, from (+)-proto-quercitol
inferred← citeshttps://doi.org/10.1016/j.carres.2016.03.007openalex-snapshot
Investigation of original multivalent iminosugars as pharmacological chaperones for the treatment of Gaucher disease
inferred← citeshttps://doi.org/10.1016/j.carres.2016.03.010openalex-snapshot
Molecular basis for the affinity and specificity in the binding of five-membered iminocyclitols with glycosidases: an experimental and theoretical synergy
inferred← citeshttps://doi.org/10.1016/j.carres.2016.09.003openalex-snapshot
One pot oxidative dehydration - oxidation of polyhydroxyhexanal oxime to polyhydroxy oxohexanenitrile: A versatile methodology for the facile access of azasugar alkaloids
inferred← citeshttps://doi.org/10.1016/j.carres.2017.03.009openalex-snapshot
N-Substituted 5-amino-1-hydroxymethyl-cyclopentanetriols: A new family of activity promotors for a G M1 -gangliosidosis related human lysosomal β-galactosidase mutant
inferred← citeshttps://doi.org/10.1016/j.cbpa.2004.04.001openalex-snapshot
Recent applications of olefin metathesis to combinatorial chemistry
inferred← citeshttps://doi.org/10.1016/j.cbpa.2008.05.010openalex-snapshot
Mechanistic insights into glycosidase chemistry
inferred← citeshttps://doi.org/10.1016/j.cca.2018.02.021openalex-snapshot
Functional and pharmacological evaluation of novel GLA variants in Fabry disease identifies six (two de novo ) causative mutations and two amenable variants to the chaperone DGJ
inferred← citeshttps://doi.org/10.1016/j.cca.2024.119843openalex-snapshot
Fabry disease Enzyme Enhancement on migalastat Study: FEES
inferred← citeshttps://doi.org/10.1016/j.ceb.2010.11.002openalex-snapshot
Chemical and/or biological therapeutic strategies to ameliorate protein misfolding diseases
inferred← citeshttps://doi.org/10.1016/j.cell.2008.06.037openalex-snapshot
Chemical and Biological Approaches Synergize to Ameliorate Protein-Folding Diseases
inferred← citeshttps://doi.org/10.1016/j.celrep.2022.111096openalex-snapshot
Pulse labeling reveals the tail end of protein folding by proteome profiling
inferred← citeshttps://doi.org/10.1016/j.ces.2021.116602openalex-snapshot
Multi-reaction kinetic modeling for the peroxidase–aldolase cascade synthesis of a D-fagomine precursor
showing the first 200 of 596 · page through all 596
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.